Kexing COVD-19 vaccines made Brazil town 80% down on infection
- Stem Cell Therapy for Inflammatory Bowel Disease
- How about the safety and efficacy of novel CAR-T therapies?
- Even mild infection with COVID-19 can trigger long-lasting neuroinflammation
- Amyotrophic Lateral Sclerosis (ALS): Two new drugs failed in clinical trials!
- The “magic drug” metformin may make people live to 120 years old!
- Why do most smokers not get lung cancer?
Kexing COVD-19 vaccines made Brazil town 80% down on infection and deaths dropped by 95%. Small towns in Brazil becomes “healthy oasis” after vaccination
Kexing COVD-19 vaccines made Brazil town 80% down on infection. Large-scale vaccination has turned a small Brazilian town into a healthy oasis,” Reuters reported on May 31.
On the same day, the Butantan Institute, a partner of Beijing Kexing Company in Brazil, officially announced the research results of the large-scale vaccination of Kexingkeleifu’s COVID-19 vaccine in the small town of Serana in the country: compared with the data at the beginning of the trial , After the full vaccination is completed, the number of new symptomatic COVID-19 cases in the local area has dropped by 80%, the number of hospitalizations has dropped by 86%, and the number of deaths has dropped by 95%.
The test also showed that Kexing vaccine can effectively fight against the new coronavirus variant strain with few adverse reactions. Ribeirao Preto, another city 20 kilometers away from Serana, was blocked due to the raging epidemic and the increase in severely ill patients. Serrana’s research results have aroused worldwide attention.
This is also the first such large-scale experiment in a certain area. The Associated Press said on the 31st that the results of the test may be a source of hope for hundreds of millions of people, especially in developing countries.
Serana is a municipality in the state of Sao Paulo, Brazil. According to a report by the Brazilian News Agency on May 31, the study called “Plan S” started on February 17 this year and ended on April 11. The city has a total of 45,644 residents. Excluding children, pregnant women, people with serious illnesses who are unwilling to be vaccinated, 27,160 adults received two doses of Kexing vaccine, accounting for about 60% of the city’s total population.
Brazil’s “G1” news network said on the 31st that the city of Serana was chosen to carry out this experiment because the city has a small population and is close to the big city Ribeirao Preto; A serological survey conducted by the city of Serana found worrying data. It is estimated that 10.6% of the city’s residents have been infected with the COVID-19 virus.
In this trial, the city of Serana divided all eligible adults into four groups: green, yellow, gray, and blue, and vaccinated in sequence, with an interval of 28 days between the two doses. According to the Brazilian News Agency, this study also shows that the threshold for curbing the epidemic is 75% of eligible adults after the second dose.
Palacios, a researcher in charge of the trial at the Butantin Institute, said at a press conference on the 31st: “This trial made us realize that the epidemic can be controlled without having to vaccinate everyone. We found that, When 70% to 75% of adults are vaccinated, the number of new cases will start to decline.” The Associated Press said that in March, 19 people died of COVID-19 pneumonia in the area, which dropped to 6 in April and May. Only 1 person.
The test results also show that after adults are vaccinated, they indirectly protect those who have not been vaccinated. “G1” said Palacios said that after the local mass vaccination, the number of infections among unvaccinated people has also decreased. “Even the elderly who have not been vaccinated have been protected. This has brought us Hope and joy”. He said that minors under the age of 18 have not been vaccinated, but there has been a decrease in children’s cases.
“G1” said that this test also proved that the Coxing vaccine also has a strong protective effect against the P.1 mutant strain circulating in Brazil. In January this year, Brazil discovered the P.1 strain for the first time, and it quickly spread to other countries and regions in the world.
Researchers tracked and analyzed the P.1 strain and found that this variant strain is more contagious and also produces immune escape. Palacios said on the 31st that the main circulating virus in Serrana is also the P.1 strain, and tests have shown that the vaccine is effective against the mutant virus. According to the Brazilian News Agency, Covas, director of the Butantan Institute, said that the conclusions of this experiment prove the effectiveness of mass vaccination in Brazil and the world, and bring hope to the control of the epidemic.
Despite the success of the experiment, all residents of the city still need to wear masks when going out and take necessary anti-epidemic measures. Covas said that the Serana test has not yet been fully completed, and the scientific researchers will continue to monitor Serana for one year.
Another important conclusion of the experiment comes from the contrast between the epidemic situation in Serana and surrounding cities. About 10,000 citizens of Serana work in Ribeirao Preto, a large city 20 kilometers away. The Associated Press reported on the 31st that Ribeirão Preto’s hospital was crowded with patients with COVID-19 pneumonia, and 95% of the beds in the local intensive care unit were occupied by patients with COVID-19, and there was a serious shortage of vaccines. The city implemented strict lockdown measures last week, including stopping public transportation and restricting the time residents can buy food.
Brazil is one of the most severely affected countries in the world. According to data reported by the Brazilian Ministry of Health, on May 31, local time, there were more than 30,000 new confirmed cases in a single day and 860 new deaths in a single day. The cumulative number of confirmed cases exceeded 16.54 million, and the cumulative number of deaths exceeded 460,000. People, second only to the United States. The Associated Press said on the 31st that Brazilian President Bolsonaro’s critic and Governor of São Paulo State, Doria, said, “If it weren’t for the delay in vaccination, what happened in Serana could have happened throughout Brazil. These results show that There is only one way to control the pandemic: vaccines, vaccines, vaccines.”
In addition to effectiveness, the study also provides safety data, that is, whether the vaccine will have an adverse effect on the vaccinated. According to reports, there were 67 “serious adverse events” among Serana vaccinated patients, but none of them were related to the vaccine. After the first vaccination, it was observed that 4.4% of the vaccinators had adverse reactions. The most serious adverse reactions were muscle pain or headache. After the second vaccination, the incidence of adverse reactions was 0.2%.
On June 1, Kexing Company held a press conference in Beijing. The company spokesperson said that Kexing has already supplied vaccines to 40 countries around the world. As of May 31, the global supply of COVID-19 vaccines has exceeded 600 million doses. According to incomplete statistics, the actual vaccination volume has exceeded 430 million doses. This means that out of every 5 new coronavirus vaccines in the world, at least one dose is supplied by Kexing.
The results of Serrana’s test also impressed the Western media who often pick Chinese vaccines. Bloomberg reported on June 1 that the trial “is the latest in a series of real evidence verifying the controversial Chinese vaccine”, indicating that Kexing vaccine “can control the COVID-19 epidemic more effectively than expected by clinical testing.” The data provided by countries that have been vaccinated widely in the past few months are generally positive.” According to Reuters, another city in Sao Paulo, Brazil’s richest state, is conducting a similar experiment. The city is expected to use the AstraZeneca vaccine to vaccinate most of its 148,000 residents.
(source:internet, reference only)
Disclaimer of medicaltrend.org